Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu
© Borgis - Postępy Nauk Medycznych 11/2015, s. 772-778
Joanna Śladowska-Kozłowska1, 2, *Mieczysław Litwin1
Polimorfizmy genu śródbłonkowej syntazy tlenku azotu u dzieci z pierwotnym nadciśnieniem tętniczym
Genetic polymorphisms of endothelial nitric oxide synthase in children with primary hypertension
1Department of Nephrology and Arterial Hypertension, The Children’s Memorial Health Institute, Warszawa
2Paediatric Practice, Darmstadt, Germany
Tlenek azotu jest główną substancją regulującą napięcie mięśni gładkich naczyń. Dysfunkcja śródbłonka i zaburzenie generacji tlenku azotu są stałym zjawiskiem obserwowanym w chorobach układu krążenia, szczególnie powikłanych cukrzycą i/lub miażdżycą. Badania dzieci z nadciśnieniem tętniczym pierwotnym pozwalają na uzyskanie dodatkowych informacji o najwcześniejszych etapach rozwoju choroby sercowo-naczyniowej niepowikłanych wpływem dodatkowych czynników ryzyka, które na ogół są obecne u dorosłych z nadciśnieniem tętniczym. W pracy przedyskutowano znaczenie polimorfizmów syntazy śródbłonkowej tlenku azotu w patogenezie nadciśnienia tętniczego pierwotnego i jego powikłań narządowych u dzieci. Wyniki dotychczasowych badań wskazują, że polimorfizm G894T śródbłonkowej syntazy tlenku azotu jest związany z zaburzeniem zależnej od śródbłonka rozszerzalności naczyń oraz z rozwojem subkliniczych uszkodzeń naczyniowych u dzieci z nadciśnieniem tętniczym pierwotnym. Zjawiska te mogą być modyfikowane przez styl życia oraz czynniki środowiskowe takie, jak dieta oraz aktywność fizyczna.
Nitric oxide (NO) is the main substance regulating vascular tone. Endothelial dysfunction and decreased production of NO is a well-known phenomenon in adults with cardiovascular disease and especially when concomitant disorders such as diabetes and atherosclerosis are present. However, there are only few data on NO, polymorphisms of endothelial NO synthase (eNOS) and endogenous inhibitors of eNOS in children with primary hypertension. Children with primary hypertension usually are not exposed to other cardiovascular risk factors such as diabetes, nicotinism and clinically evident atherosclerosis. Thus, children with primary hypertension present the first step of development of cardiovascular disease and allow study of pathogenesis of cardiovascular disease not disturbed by influence of other disorders. We discuss findings from studies evaluating polymorphisms of eNOS and especially of G894T polymorphism and endogenous inhibitors of eNOS in hypertensive children and children with cardiovascular risk factors. G894T polymorphism has been established a functional mutation that is associated with a blunted endothelial-dependent vasodilation and is associated with an increased risk of cardiovascular disease and early vascular changes observed especially in young hypertensive subjects. Although there are no data that eNOS polymorphisms are associated with development of PH, there is evidence that eNOS G894T polymorphism is associated with early subclinical arterial injury in early phase of cardiovascular disease, i.e. in adolescents with PH. However, effects of genetic polymorphisms of eNOS may be modified by behavioral and environmental factors.

Primary hypertension (PH) in childhood and adolescence is not a benign disease and causes significant target organ damage (TOD) present in 30-40% of children already at the diagnosis of elevated blood pressure (BP) (1-5). The main intermediate phenotypes of children with PH are metabolic abnormalities typical of metabolic syndrome, oxidative stress and immune activation. Moreover, these abnormalities are also strictly associated with TOD (6-10). Pathogenesis of PH is multifactorial and it seems that different mechanisms are responsible for elevation of blood pressure and development of TOD. However, these mechanisms are interrelated. For instance, elevation of BP may lead to increase of carotid intima-media thickness (cIMT) and arterial stiffness and increased arterial stiffness causes elevation of BP. Moreover, not all hypertensive patients develop TOD. It suggests that some subjects, and in a case of so common diseases as PH, some part of population, is susceptible to development of TOD and as the consequence, to cardiovascular events (11). Heritability studies suggest that interindividual differences of blood pressure (BP) values are, at least in part, explained by genetic factors (40-60%) (12). However, the interaction of age, gender, ethnicity, diet, used medicines and lifestyle behavior complicates these analyses (13). It is evidenced that the functional impact of genetic polymorphisms on cardiovascular disease is greatest among subjects with lower overall risk (14-16). Since children are relatively free of the common environmental and concomitant clinical factors contributing to cardiovascular disease, the genetic associations exerting theirs effects during the long preclinical phase that begins in childhood, are suspected to be more significant (17, 18).
Human and animal studies point to a number of candidate genes, which may be involved in the development of PH and cardiovascular complications but may also interact with environmental parameters. Because PH is a disease of the arterial tree characterized by increased IMT and arterial stiffening, factors influencing endothelial function are potential modulators of susceptibility to develop PH and TOD. Nitric oxide (NO) has been established as a key signaling molecule in vascular homeostasis. Thus, polymorphisms in the gene that encodes endothelial nitric oxide synthase (eNOS) are of interest because of its potential to affect development of PH and TOD (19).
Nitric oxide and endothelial nitric oxide synthase
The discovery of NO, previously known as endothelium-derived relaxing factor, was one of the most significant biological achievements of the 20th century distinguished by the Nobel Prize in Medicine in 1998. Simple NO molecule is a regulator of many physiological processes. It is synthesized by vascular endothelial cells, it is responsible for vasodilatation and is involved in various processes in the nervous, reproductive and immune systems (20). NO is involved in a wide variety of regulatory mechanisms of the cardiovascular system, including vascular tone (i.e. it is the major mediator of endothelium dependent vasodilatation) and vascular structure (e.g. inhibition of smooth muscle cell proliferation), and cell-cell interactions in blood vessels (e.g. inhibition of platelet adhesion and aggregation, inhibition of monocyte adhesion, cytostatic and cytotoxic properties) (20, 21). In addition to its participation in the regulation of vascular smooth muscle tone, NO directly affects mitochondrial respiration and plays important roles in the development of metabolic syndrome (MS) components, such as insulin resistance, endothelial dysfunction, hypertriglyceridemia and chronic adipose tissue inflammation and is involved in different mitochondrial signaling pathways that control respiration and apoptosis (22, 23).
Moreover, impaired NO bioavailability could also be related to a cellular defect in skeletal muscle tissue, where NO regulates metabolic and contractile processes and also basal, insulin-independent glucose transport (24). Experiments with homozygous eNOS knockout mice have definitively proven the relationship between NO and insulin sensitivity because these mice showed increased blood pressure and insulin resistance (25).
Because of these multiple functions, NO is regarded as an endogenous antiatherosclerotic molecule and tight control of NO production is believed to be critically important for the maintenance of cellular and tissue homeostasis (20, 21). There is hardly a disease not associated with altered NO homeostasis and endothelial dysfunction has become synonymous with reduced biological activity of NO. Thus, endothelial- and NO-dysfunction is a hallmark of not only cardiovascular disease and hypertension but also of obesity, diabetes, malnutrition (26).
There are data indicating on the involvement of eNOS in the pathogenesis of PH and the association of a relative or absolute decrease of eNOS activity with various vascular complications in response to hemodynamic workload (27). There are also data indicating that relative or absolute defect in the production of NO by eNOS or an abundant degradation of NO by enhanced oxidative stress (reactive oxygen species) is associated with various vascular complications in response to hemodynamic workload (27, 28).
NO is an essential molecule, nevertheless, its production is not always beneficial, as an excess or diminished NO production can have detrimental effects. Furthermore, cellular effects of NO may depend not only on its concentration, but also on its site of release and duration of action (29). The discrepant beneficial and detrimental effects that have been ascribed to NO may depend on closely regulated levels of NO in the vessel wall (30, 31). Within endothelial cells that line the lumen of all blood vessels eNOS catalyzes calcium-calmodulin-dependent NO synthesis through the conversion of L-arginine to L-citrulline (32). The normal function of eNOS requires dimerization of the enzyme, the presence of the substrate L-arginine and the essential cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), one of the most potent naturally occurring reducing agents. Diminished levels of BH4 or L-arginin have been attributed to the failure of eNOS to form dimers. In monomeric form eNOS (referred to as eNOS uncoupling) catalyzes the reduction of molecular oxygen to the free radical superoxide (O2-) instead of NO. Moreover O2- reacts avidly with NO and forms peroxynitrite (ONOO-), a much more powerful oxidant, which in turn also leads to eNOS uncoupling and enzyme dysfunction.
Superoxide is a free radical which rapidly reacts with NO reducing its bioactivity and producing peroxynitrite; a strong oxidant that can nitrosylate cellular proteins and lipoproteins (33-35). Recent evidence suggests that increased superoxide production accounts for a significant proportion of the NO deficit in several animal models of vascular disease, including hypercholesterolemia, hypertension, and heart failure (36). In addition to effects mediated by scavenging NO, superoxide directly stimulates mitogenesis in vascular smooth muscle cells and reduces eNOS expression and activity in endothelial cells (36, 37).
Potential sources of vascular superoxide production include nicotinamide adenine dinucleotide phosphate (NAD(P)H)-dependent oxidases, xanthine oxidase, lipoxygenase, mitochondrial oxidases, and NO synthases (36). NAD(P)H oxidases represent major sources of this reactive oxygen species and have been found upregulated and activated in animal models of hypertension, diabetes, and sedentary lifestyle and in patients with cardiovascular risk factors (38). Peroxynitrite, the direct reaction product of NO· and O2-, interacts with lipids, DNA, and proteins via direct oxidative reactions or via indirect, radical-mediated mechanisms. These reactions trigger cellular responses ranging from subtle modulations of cell signaling to overwhelming oxidative injury, committing cells to necrosis or apoptosis (20). It is important to note that particularly ONOO-, is able to oxidize BH4 to the BH3· radical (38).
The plasma membrane invaginations that form caveolae are also critical for modulation of eNOS activity. Indeed, it is within caveolae that eNOS attains maximal activity and interacts with CAV-1, a 21-24 kDa protein that coats the cytoplasmic surface of caveolae. In caveolae, eNOS activation is modulated through direct-steric inhibition of calmodulin binding with caveolin (39, 40). Agonist activation (or stimulation by shear stress) increases intracellular calcium and calcium-calmodulin binding, which displaces caveolin and reverses its inhibitory effect on eNOS. In addition to this tonic inhibition, interaction with CAV-1 contributes to eNOS concentration in caveolae. A substantial proportion of active eNOS resides in the peri-Golgi area, proper caveolar localization is critical for eNOS activation and maximal activity (41). Reduced activity of eNOS observed in arterial hypertension, can be caused by increased bonding between eNOS and CAV-1, which inhibits the activity of eNOS. CAV-1 binds eNOS via both the caveolin scaffolding domain and its carboxy-terminal domain. Via this interaction, CAV-1 inhibits eNOS function and NO generation. On the contrary, loss of CAV-1 leads to eNOS hyperactivation and uncontrolled NO overproduction. Excess NO, secondary to the loss of CAV-1, induces mitochondrial dysfunction and aerobic glycolysis, via NO effects on the electron transport system, and interactions of NO with free radicals what generates peroxynitrites (42).
Under normal, basal conditions in blood vessels, NO is steadily produced by eNOS and determines vascular tonus. The activity of eNOS is calcium- and calmodulin-dependent. There are two basic pathways for the stimulation of eNOS, and both of them involve release of calcium ions from subsarcolemmal storage sites. First, shearing forces acting on the vascular endothelium generated by blood flow causes a release of calcium and subsequent eNOS activation. Therefore, an increase in blood flow stimulates NO formation (flow--dependent NO formation). Second, endothelial receptors for a variety of ligands stimulate calcium release and subsequent NO production (receptor-stimulated NO formation). Included are receptors for acetylcholine, bradykinin, substance-P, adenosine, and many others vasoactive substances.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. Sorof J, Alexandrov A, Garami Z et al.: Carotid ultrasonography for detection of vascular abnormalities in hypertensive children. Pediatr Nephrol 2003; 18: 1020-1024.
2. Hanevold C, Waller J, Daniels S et al.: International Pediatric Hypertension Association: the effects of obesity, gender and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics 2004; 113: 328-333.
3. Litwin M, Niemirska A, Śladowska J et al.: Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol 2006; 21: 811-819.
4. McNiece KL, Gupta-Malhotra M, Samuels J et al.: Left ventricular hypertrophy in hypertensive adolescents. Analysis of risk by 2004 National High Blood Pressure Education Program Working Group criteria. Hypertension 2007; 50: 392-395.
5. Levy D, Garrison RJ, Savage DD et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
6. Litwin M, Śladowska J, Antoniewicz J et al.: Metabolic abnormalities, insulin resistance and metabolic syndrome in children with primary hypertension. Am J Hypertens 2007; 20: 875-882.
7. Śladowska-Kozłowska J, Litwin M, Niemirska A et al.: Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. Pediatr Nephrol 2012; 27: 1943-1951.
8. Flynn J, Falkner B: Obesity Hypertension in Adolescents: Epidemiology, Evaluation, and Management. J Clin Hypertens 2011; 13: 323-331.
9. Litwin M, Michałkiewicz J, Niemirska A et al.: Inflammatory activation in children with primary hypertension. Pediatr Nephrol 2010; 25: 1711-1718.
10. Assadi F: Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 2007; 28: 27-33.
11. Flynn J: Hypertension in the young: epidemiology, sequelae and therapy Nephrol Dial Transplant 2009; 24: 370-375.
12. Snieder H, Harshfield G, Treiber F: Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension 2003; 41: 1196-1201.
13. Kunes J, Zicha J: The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res 2009; 58: S33-S41.
14. Wolff B, Braun C, Schlüter C et al.: Endothelial nitric oxide synthase Glu(298)?Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clin Sci (Lond) 2005; 109: 475-481.
15. Risch NJ: Searching for genetic determinants in the new millennium. Nature (London) 2000; 405: 847-856.
16. Paradossi U, Ciofini E, Clerico A et al.: Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298?Asp and T-786?C polymorphisms. Stroke 2004; 35: 1305-1309.
17. Leeson C, Hingorani A, Mullen M et al.: Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90: 1153-1158.
18. Barath A, Endreffy E, Bereczki C et al.: Endothelin-1 gene and endothelial nitric oxide synthase gene polymorphisms in adolescents with juvenile and obesity-associated hypertension. Acta Physiologica 2007; 94: 49-66.
19. Lembo G, De Luca N, Battagli C et al.: A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001; 32: 735-740.
20. Pacher P, Beckman J, Liaudet L: Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev 2007; 87: 315-424.
21. Böger R: Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the “L-Arginine Paradox” and Acts as a Novel Cardiovascular Risk Factor. J Nutr 2004; 134: 2842S-2847S.
22. Lee H, Cho Y, Kwak S et al.: Mitochondrial dysfunction and metabolic syndrome-looking for environmental factors. Biochim Biophys Acta 2010; 1800: 282-289.
23. Litvinova L, DmitriyN, Atochin D et al.: Nitric oxide and mitochondria in metabolic syndrome. Front Physiol 2015; 6(20): 1-10.
24. Kapur S, Bedard S, Marcotte B et al.: Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 1997; 46: 1691-1700.
25. Shankar R, Wu Y, Shen H et al.: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000; 49: 684-687.
26. Yetik-Anacak G, Catravas JD: Nitric oxide and the endothelium: History and impact on cardiovascular disease. Vascular Pharmacology 2006; 45: 268-276.
27. Ignarro L, Cirino G, Casini A, Napoli C: Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 34: 879-886.
28. Cai H, Harrison D: Endothelial Dysfunction in Cardiovascular Diseases. The Role of Oxidant Stress. Circ Res 2000; 87: 840-844.
29. Chen H, Xing B, LiuX et al.: Ozone oxidative preconditioning protects the rat kidney from reperfusion injury: the role of nitric oxide. J Surg Res 2008; 149: 287-295.
30. Iwata A, Sai S, Moore M et al.: Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase. J Heart Lung Transplant 2000; 19: 1017-1028.
31. Artifoni L, Benetti E, Centi S: The impact of eNOS, MTR and MTHFR polymorphisms on renal graft survival in children and young adults. Nephrol Dial Transplant 2009; 24: 2931-2937.
32. Förstermann U, Pollock J, Schmidt H et al.: Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 1788-1792.
33. Gryglewski RJ, Palmer RM, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-456.
34. White C, Brock T, Chang L et al.: Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 1044-1048.
35. Darley-Usmar VM, Hogg N, O’Leary VJ et al.: The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun 1992; 17: 9-20.
36. Guzik T: Vascular Superoxide Production by NAD(P)H Oxidase Association With Endothelial Dysfunction and Clinical Risk Factors. Circ Res 2000; 86: e85-e90.
37. Peterson TE, Poppa V, Ueba H et al.: Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999; 85: 29-37.
38. Forstermann U, Münzel T: Endothelial Nitric Oxide Synthase in Vascular Disease. From Marvel to Menace. Circulation 2006; 113: 1708-1714.
39. Michel JB, Feron O, Sacks D, Michel T: Reciprocal regulation of endothelial nitric oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997; 272: 15583-15586.
40. Testa A, Spoto B, Sanguedolce M et al.: eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. American Journal of Hypertension 2012; 25: 103-108.
41. Rahman A, Swärd K: The role of caveolin-1 in cardiovascular regulation. Acta Physiol (Oxf ) 2009; 195: 231-245.
42. Chen Z, Bakhshi F, Shajahan A et al.: Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Mol Biol Cell 2012; 23: 1388-1398.
43. Sydow K, Munzel T: ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.
44. Goonasekera CD, Rees DD, Woolard P et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-909.
45. Antoniades C, Shirodaria C, Leeson P et al.: Association of plasma asymetrical dimethylarginine with elevated vasclar superoxide production and endothelial nitric oxide synthase uncoupling: implication for endothelial function in human atherosclerosis. Eur Heart J 2009; 30: 1142-1150.
46. Ayer J, Harmer J, Nakhla S et al.: HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Atheroscler Thromb Vasc Biol 2009; 29: 943-949.
47. Perticone F, Sciacqua A, Maio R et al.: Endothelial dysfunction, ADMA and insulin resistance in essentials hypertension. Int J Cardiol 2010; 142: 236-241.
48. Sydov K, Mondon C, Cooke J: Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 2005; 10: 35-43.
49. Stühlinger M, Abbasi F, Chu J et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426.
50. Markus H, Ruigrok Y, Ali N, Powell J: Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma. Stroke 1998; 29: 1908-1911.
51. Metzger I, Sertório J, Tanus-Santos J: Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 2007; 43: 987-992.
52. Hingorani A: Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 2001; 154: 521-527.
53. Wang X, Wang J: Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 2000; 70: 241-251.
54. Jones A, Hingorani D: Genetic regulation of endothelial function. Heart 2005; 91: 1275-1277.
55. Nakayama M, Yasue H, Yoshimura M et al.: T-786RC mutation in the 5’- flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-2870.
56. Cattaruzza M, Guzik TJ, Slodowski W et al.: Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004; 95: 841-847.
57. Casas J, Hingorani A, Humphries S et al.: Do meta-analyses of association studies of endothelial nitric oxide synthase variants and ischemic heart disease provide conclusive answers? Circulation 2004; 110: e305-306.
58. Chamberlain JG, Galton DJ: Genetic susceptibility to atherosclerosis. Br Med Bull 1990; 46: 917-940.
59. Hingorani A, Liang C, Fatibene J et al.: A common variant of the endothelial nitric oxide synthase (Glu298?Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-1520.
60. Hibi K, Ishigami T, Tamura K et al.: Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32: 521-526.
61. Colombo M, Andreassi M, Paradossi U et al.: Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298?Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 2002; 87: 525-528.
62. Czarnecka D, Kawecka-Jaszcz K, Stolarz K et al.: Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study. J Hum Hypertens 2005; 19: 413-420.
63. Karvonen J, Kauma H, Kervinen K et al.: Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort. J Intern Med 2002; 251: 102-110.
64. Neves F, Silva B, Rocha N et al.: Effect of the 894G>T polymorphism of the endothelial nitric oxide synthase on vascular reactivity following maximal dynamic exercise. J Hypertens 2010; 28: 764-770.
65. Marroni A, Metzger I, Souza-Costa D et al.: Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 2005; 12: 177-182.
66. Niu W, Qi Y: An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 2011; 6: e24266.
67. Tanus-Santos J, Desai M, Flockhart D: Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-725.
68. Souza-Costa D, Belo V, Silva P et al.: eNOS haplotype associated with hypertension in obese children and adolescents. Int J Obes (Lond) 2011; 35: 387-392.
69. Miranda J, Belo V, Souza-Costa D et al.: eNOS polymorphism associated with metabolic syndrome in children and adolescents. Mol Cell Biochem 2013; 372: 155-160.
70. Śladowska-Kozłowska J, Litwin M, Niemirska A et al.: Association of the eNOS G894T gene polymorphism with target organ damage in children with newly diagnosed primary hypertension. Pediatr Nephrol 2015, 30: 2189-97.
71. Antoniades C, Tousoulis D, Vasiliadou C et al.: Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol 2005; 46: 1101-1109.
72. Grontved A, Andersen L, Franks P et al.: NOS3 variants, physical activity, and blood pressure in the European Youth Heart Study. Am J Hypertens 2011; 24: 444-450.
73. Godfrey V, Chan S-L, Cassidy A et al.: The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers. Cardiovasc Drug Rev 2007; 25: 280-288.
74. Jimènez-Morales A, Ruano J, Delgado-Lista J et al.: NOS3 Glu298Asp polymorphism interacts with virgin olive oil phenols to determine the postprandial endothelial function in patients with the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: 1694-1702.
75. Sofowora G, Dishy V, Xie H et al.: In vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 11: 809-818.
76. Tesauro M, Thompson W, Rogliani P et al.: Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate versus glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832-2835.
77. Ahmadi KR, Weale ME, Xue et al.: A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37: 84-89.
78. Fairchild T, Fulton D, Fontana J et al.: Acidic hydrolysis as a mechanism for the cleavage of the Glu298-Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674-26679.
79. Joshi MS, Mineo C, Shaul PW et al.: Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 2007; 21: 2655-2663.
80. Gruber H, Mayer C, Mangge H et al.: Obesity reduces the bioavailability of nitric oxide in juveniles. Int J Obes Lond 2008; 32: 826-831.
81. de Moraes A, Fernández-Alvira J, Carvalho H et al.: Physical activity modifies the associations between genetic variants and blood pressure in European adolescents. J Pediatr 2014; 165: 1046-1049.
otrzymano: 2015-09-08
zaakceptowano do druku: 2015-09-30

Adres do korespondencji:
*Mieczysław Litwin
Department of Nephrology and Arterial Hypertension The Children’s Memorial Health Institute
Aleja Dzieci Polskich 20, 04-730 Warszawa
tel. +48 (22) 815-15-40
fax +48 (22) 815-15-39

Postępy Nauk Medycznych 11/2015
Strona internetowa czasopisma Postępy Nauk Medycznych